CT1812 100 mg for Lewy Body Disease

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Lewy Body Disease+2 More
CT1812 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial tests whether the study drug is better than placebo at improving thinking and memory in people with mild to moderate dementia with Lewy bodies.

Eligible Conditions
  • Lewy Body Disease
  • Dementia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: Baseline, 3 months, 6 months

Month 6
ADCS - Activities of Daily Living (ADCS-ADL)
ADCS-Clinical Global Impression of Change (CGIC)
Clinical Assessment of Fluctuation (CAF)
Cognitive Drug Research Battery (CDR)
Epworth Sleepiness Scale (ESS)
Montreal Cognitive Assessment Scale (MoCA)
Movement Disorder Society - United Parkinson's Disease Rating Scale Part III (MDS-UPDRS Part III)
Neuropsychiatric Inventory (NPI)
Day 210
Safety and Tolerability of CT1812

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

3 Treatment Groups

CT1812 100 mg
1 of 3
CT1812 300 mg
1 of 3
Placebo
1 of 3

Active Control

Non-Treatment Group

120 Total Participants · 3 Treatment Groups

Primary Treatment: CT1812 100 mg · Has Placebo Group · Phase 2

CT1812 100 mg
Drug
ActiveComparator Group · 1 Intervention: CT1812 · Intervention Types: Drug
CT1812 300 mg
Drug
ActiveComparator Group · 1 Intervention: CT1812 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: CT1812 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 3 months, 6 months

Who is running the clinical trial?

National Institute on Aging (NIA)NIH
1,385 Previous Clinical Trials
3,474,866 Total Patients Enrolled
21 Trials studying Lewy Body Disease
18,565 Patients Enrolled for Lewy Body Disease
Cognition TherapeuticsLead Sponsor
10 Previous Clinical Trials
884 Total Patients Enrolled
Anthony Caggiano, MDStudy DirectorCognition Therapeutics Inc.
4 Previous Clinical Trials
727 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing to comply with acceptable form of contraception or you are not pregnant.
Subjects or their LAR must provide written informed consent to the study prior to any study procedures.
Subjects shall be generally healthy with mobility, vision and hearing sufficient for compliance with testing procedures.
You have a minimum age of 50 years, and you meet the criteria for probable DLB.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: November 18th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.